Capital Research Global Investors
TAK icon

Capital Research Global Investors’s Takeda Pharmaceutical TAK Stock Holding History

Capital Research Global Investors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309M Buy
19,297,680
+193,461
+1% +$3.2M 0.04% 200
2026
Q1 		$354M Buy
19,104,219
+5,617,447
+42% +$98.6M 0.05% 195
2025
Q4 		$210M Buy
13,486,772
+82,643
+0.6% +$1.18M 0.04% 223
2025
Q3 		$196M Buy
13,404,129
+108,556
+0.8% +$1.61M 0.04% 223
2025
Q2 		$206M Buy
13,295,573
+94,569
+0.7% +$1.4M 0.04% 220
2025
Q1 		$196M Buy
13,201,004
+38,491
+0.3% +$539K 0.04% 222
2024
Q4 		$174M Buy
13,162,513
+25,309
+0.2% +$348K 0.04% 238
2024
Q3 		$187M Buy
13,137,204
+10,596
+0.1% +$150K 0.04% 226
2024
Q2 		$170M Buy
13,126,608
+4,678
+0% +$61.9K 0.04% 233
2024
Q1 		$182M Sell
13,121,930
-1,175,875
-8% -$17.1M 0.04% 235
2023
Q4 		$204M Buy
14,297,805
+503,446
+4% +$7.14M 0.05% 230
2023
Q3 		$213M Buy
13,794,359
+6,518
+0% +$101K 0.06% 220
2023
Q2 		$217M Buy
13,787,841
+208,381
+2% +$3.41M 0.06% 225
2023
Q1 		$224M Buy
13,579,460
+10,903,323
+407% +$174M 0.06% 210
2022
Q4 		$41.7M Buy
+2,676,137
New +$37.4M 0.01% 346
2021
Q1 		– Sell
-65,430
Closed -$1.19M – 439
2020
Q4 		$1.19M Buy
65,430
+10,055
+18% +$176K ﹤0.01% 393
2020
Q3 		$1M Buy
55,375
+4,042
+8% +$73.6K ﹤0.01% 393
2020
Q2 		$930K Buy
51,333
+15,672
+44% +$281K ﹤0.01% 392
2020
Q1 		$557K Buy
35,661
+10,615
+42% +$192K ﹤0.01% 383
2019
Q4 		$492K Buy
25,046
+5,490
+28% +$105K ﹤0.01% 396
2019
Q3 		$339K Buy
+19,556
New +$338K ﹤0.01% 403

Other funds holding TAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Capital Research Global Investors's TAK Position: Q2 2026 in Review

Capital Research Global Investors increased its Takeda Pharmaceutical (TAK) stake by 1% in Q2 2026, buying an estimated $3.2M and bringing the position to 19,297,680 shares worth $309M. The position accounts for 0.04% of the portfolio, ranked #200.

Capital Research Global Investors first reported a position in TAK in Q3 2019 and has held it in 21 quarters since. The position peaked at $354M in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Capital Research Global Investors held 19,297,680 shares of Takeda Pharmaceutical worth $309M as of Q2 2026.
  • Capital Research Global Investors bought 193,461 Takeda Pharmaceutical shares in Q2 2026, an estimated $3.2M.
  • Takeda Pharmaceutical made up 0.04% of Capital Research Global Investors's portfolio in Q2 2026, its #200 holding.
  • Capital Research Global Investors first reported a position in Takeda Pharmaceutical in Q3 2019 and has held it in 21 quarters since.
  • Capital Research Global Investors's Takeda Pharmaceutical position peaked at $354M in Q1 2026.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.